Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATENCY-1: PRT-201 in Radiocephalic AVF Creation
NCT02110901Phase 3Completed
- Sponsor
- Proteon Therapeutics
- Start
- Jul 2014
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing PRT-201 Arm with Placebo Arm (2 arms). Primary endpoints: Time to AVF Primary Unassisted Patency at 1 year and Kaplan-Meier Estimate of Secondary AVF Patency at 1 year. Started Jul 2014; status: completed.
02
Drugs
vonapanitase
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02110901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110901.